在长期吸烟者中,L-氨酸使冠心血管运动正常化
R Campisi1, J Czernin, H Schöder
1Department of Molecular and Medical Pharmacology, UCLA School of Medicine, and Laboratory of Structural Biology and Molecular Medicine, University of California, Los Angeles, 90095-1735, USA.
Circulation
|February 2, 1999
概括
长期吸烟者表现出异常的冠状动脉血管反应,但补充L-氨酸可以逆转这种功能障碍,表明内皮干扰. 这项研究突出了PET成像技术.
科学领域:
- 心血管生理学心血管生理学
- 内皮功能研究研究 内皮功能研究
- 核心脏病学 核心脏病学
背景情况:
- 使用PET进行的非侵入性心肌血流量 (MBF) 测量显示,在健康的长期吸烟者中,冠状动脉血管运动对寒冷压力测试的反应受损.
- 假设冠状动脉内皮功能障碍,一个潜在的原因,可以通过L-氨酸,氧化合成酶的基质逆转.
研究的目的:
- 调查冠状动脉内皮功能障碍在吸烟者观察到的异常血管运动反应中的作用.
- 为了确定L-氨酸补充剂是否可以恢复正常的血管运动功能,以应对吸烟者的冷压测试.
主要方法:
- 使用13N标记的氨和PET在11名健康吸烟者和12名年龄相匹配的非吸烟者身上量化MBF.
- 静脉注射L-氨酸并分别进行冷压器测试,以评估休息和压力期间的MBF反应.
主要成果:
- 与非吸烟者相比,吸烟者在冷压力测试中表现出MBF的大幅增加 (增加11%和44%).
- 在服用L-氨酸后,在吸烟者和非吸烟者之间,MBF对冷压器测试的反应变得相似 (两组都增加了48%).
- 在任何一组中,L-氨酸都没有影响休息的MBF.
结论:
- 这些发现表明冠状动脉内皮是长期吸烟者血管运动反应异常的主要部位.
- 结合冷压器测试和PET成像,可以作为一种非侵入性方法来识别人类冠状动脉内皮功能障碍.
相关概念视频
01:28Nitric Oxide Signaling Pathway
Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure to...
01:26Coronary Artery Disease II: Pathophysiology
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
01:26Coronary Artery Disease IV: Preventive Measures
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
01:27Coronary Artery Disease V: Interprofessional Care
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
01:26Angina IV: Management
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...